
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Unicycive Therapeutics in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.13) per share for the year, up from their previous estimate of ($1.38). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $1.83 EPS, FY2029 earnings at $2.28 EPS and FY2030 earnings at $2.59 EPS.
Several other analysts also recently weighed in on the company. Guggenheim restated a “buy” rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Benchmark reissued a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. B. Riley Financial restated a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.25.
Unicycive Therapeutics Price Performance
Shares of Unicycive Therapeutics stock opened at $3.35 on Thursday. The firm has a market cap of $93.30 million, a price-to-earnings ratio of -2.01 and a beta of 1.91. Unicycive Therapeutics has a 1 year low of $3.33 and a 1 year high of $8.74. The company has a 50-day moving average of $4.03 and a 200 day moving average of $5.86.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.10.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in UNCY. Goldman Sachs Group Inc. increased its stake in Unicycive Therapeutics by 80.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after acquiring an additional 117,463 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics during the first quarter worth $940,000. Seven Fleet Capital Management LP boosted its stake in shares of Unicycive Therapeutics by 85.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after purchasing an additional 47,700 shares during the period. Virtu Financial LLC grew its stake in shares of Unicycive Therapeutics by 412.4% during the third quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock valued at $279,000 after buying an additional 47,874 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Unicycive Therapeutics in the second quarter worth $248,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.
Trending Headlines about Unicycive Therapeutics
Here are a few of the latest headlines about UNCY:
- Positive Sentiment: HC Wainwright raised several 2026–27 EPS estimates, kept its Buy rating, and reiterated a $13 price target—potential support for the stock. HC Wainwright forecast article
- Negative Sentiment: A report said Unicycive’s third-quarter loss widened to $7.0 million, highlighting ongoing losses. Article on Unicycive’s Q3 loss
- Negative Sentiment: Despite raising near-term estimates, HC Wainwright cut its 2028–30 EPS forecasts substantially. Noble Financial also lowered its 2026 estimates, adding a more cautious note to the outlook. Analyst estimate reports
About Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
